Progress of Clinical Studies on Programmed Death-1/Programmed Death-Ligand 1 Inhibitors Combined with Angiogenesis Inhibitors in the Treatment of Advanced Hepatocellular Carcinoma
Targeted therapy combined with immunotherapy is playing an increasingly important role in advanced hepatocellular carcinoma,in which programmed death-1(PD-1)/programmed death-ligand 1(PD-L1)inhibitors combined with angiogenesis inhibitors have significant efficacy and acceptable toxicity in patients with advanced hepatocytes.Angiogenesis inhibitors can not only normalize the tumor vascular system,but mediate the immune microenvironment and enhance the efficacy of PD-1/PD-L1 inhibitors.This paper summarizes the first-line treatment of advanced hepatocellular carcinoma with PD-1/PD-L1 inhibitors combined with angiogenesis inhibitors,generalizes the mechanism of action of the combined treatment,reviews and analyzes the clinical studies and differences of these first-line treatment regimens,and discusses the real-world studies,so as to provide a new direction and idea for the subsequent treatment strategy of advanced hepatocellular carcinoma.
万方数据
维普
